NCT02192099终止2 期
Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
Naurex, Inc, an affiliate of Allergan plc10 个研究点 分布在 1 个国家目标入组 61 人开始时间: 2014年9月8日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 61
- 试验地点
- 10
- 主要终点
- The Number of Participants Who Experience an Adverse Event Over the Course of the Study.
研究概览
简要总结
Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202.
详细描述
Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202 in an open label extension trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants who have completed 8 weeks of treatment in the preceding study (GLYX13-C-202, NCT
- •Participants who wish to continue treatment with GLYX-13 after the preceding study.
- •Meets Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) criteria for major depressive disorder (MDD).
- •Female subjects of childbearing potential with a negative serum pregnancy test prior to entry into the study and who are practicing an adequate method of birth control (eg oral or parenteral contraceptives, intrauterine device, barrier, abstinence) and who do not plan to become pregnant during the course of the study. Female subjects may be included without a negative serum pregnancy test if they are surgically sterile or at least 2 years post-menopausal.
- •Clinical laboratory values <2 times the upper limit of normal (ULN) or deemed not clinically significant per the investigator and Naurex medical monitor.
- •Ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments.
- •Based on the investigator and Naurex medical monitor's clinical judgment, subjects with eating disorders, obsessive compulsive disorder (OCD), panic disorder, post-traumatic stress disorder (PTSD), and generalized anxiety disorders secondary to major depressive episodes (MDEs) are permitted.
排除标准
- •Axis I diagnosis of delirium, dementia, dysthymia, amnestic or other cognitive disorder, schizophrenia or other psychotic disorder, bipolar I or II disorder, eating disorder (anorexia or bulimia nervosa), obsessive-compulsive disorder, panic disorder, acute stress disorder, agoraphobia, social phobia, attention-deficit hyperactivity disorder (ADHD), or PTSD.
- •A clinically significant current Axis II diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder
- •Experiencing hallucinations, delusions, or any psychotic symptomatology in the current episode; lifetime history of psychosis.
- •Huntington's, Parkinson's, Alzheimer's, Multiple Sclerosis, or a history of seizures or strokes.
- •Currently hospitalized or residing in an in-patient facility during study participation.
- •Substance abuse since the end of participation in GLYX13-C-202, including greater than or equal to 5 units of alcohol per day where 1 unit = ½ pint of beer, 1 glass of wine 4 oz, or 1 oz. of spirits consumed most weeks or in the opinion of the investigator
- •Women who are planning to become pregnant during the course of the study.
- •Allergy or intolerance to current antidepressant or other current medications.
- •Participation in any clinical trial of an investigational product or device within 30 days of enrollment in this trial with the exception of GLYX13-C-
- •Positive screen for drugs of abuse: cocaine, marijuana, PCP, ketamine, opioid or other agent that in the opinion of the investigator is being abused
- •Pose current (past 6 months) suicide risk based on administration of the C SSRS and the investigator's clinical judgment.
- •Human immunodeficiency virus (HIV) infection (based on the based on the HIV-1 & HIV-2 antibody screen) or other ongoing infectious disease.
研究组 & 干预措施
Rapastinel (225 mg/450 mg IV administration) prefilled syringe
Experimental
Investigators began treatment in RAP-MD-05 based on the dose level to which the patient was assigned during participation in GLYX13-C-202; patients originally assigned to rapastinel 5 mg/kg received rapastinel 225 mg, and patients originally assigned to rapastinel 10 mg/kg received rapastinel 450 mg. Investigators had the option to decrease the dose level from 450 to 225 mg if a patient experienced an adverse event(s) that the investigator believed may be associated with rapastinel
干预措施: Rapastinel (225 mg/450 mg IV administration) (Drug)
结局指标
主要结局
The Number of Participants Who Experience an Adverse Event Over the Course of the Study.
时间窗: 48 Months
An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A TEAE was an AE that occurred after receiving the first dose of investigational product or an AE present prior to first dose but increased in severity during the Treatment Period.
次要结局
未报告次要终点
研究者
研究点 (10)
Loading locations...
相似试验
进行中（未招募）
2 期
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)NCT04280718argenx229
进行中（未招募）
2 期
Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)FSHDFSHD1FSHD2FMDFMD2Fascioscapulohumeral Muscular DystrophyFascioscapulohumeral Muscular Dystrophy Type 1Fascioscapulohumeral Muscular Dystrophy Type 2Dystrophies, Facioscapulohumeral MuscularDystrophy, Facioscapulohumeral MuscularFacioscapulohumeral Muscular Dystrophy 1Facioscapulohumeral Muscular Dystrophy 2Facio-Scapulo-Humeral DystrophyAtrophy, FacioscapulohumeralAtrophies, FacioscapulohumeralFacioscapulohumeral AtrophyMuscular DystrophiesMuscular Dystrophy, FacioscapulohumeralFSH Muscular DystrophyLandouzy Dejerine DystrophyLandouzy-Dejerine Muscular DystrophyDystrophies, Landouzy-DejerineDystrophy, Landouzy-DejerineLandouzy-Dejerine SyndromeMuscular Dystrophy, Landouzy DejerineFSHProgressive Muscular DystrophyNCT06547216Avidity Biosciences, Inc.84
已完成
2 期
A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350Rheumatoid ArthritisNCT02983227Genentech, Inc.496
已完成
3 期
A Safety Study of Galcanezumab in Participants With Migraine, With or Without AuraMigraineNCT02614287Eli Lilly and Company270
已完成
2 期
Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)Duchenne Muscular DystrophyNCT00758225Santhera Pharmaceuticals21